Infinity Pharmaceuticals (NASDAQ:INFI) Lifted to Hold at ValuEngine

ValuEngine upgraded shares of Infinity Pharmaceuticals (NASDAQ:INFI) from a sell rating to a hold rating in a research note issued to investors on Thursday, ValuEngine reports.

Several other equities analysts have also recently commented on the stock. Oppenheimer initiated coverage on shares of Infinity Pharmaceuticals in a research note on Thursday, June 27th. They set an outperform rating and a $3.00 target price on the stock. CIBC initiated coverage on shares of Infinity Pharmaceuticals in a research report on Thursday, June 27th. They set an outperform rating for the company. Finally, Zacks Investment Research lowered shares of Infinity Pharmaceuticals from a buy rating to a hold rating in a research report on Thursday, April 11th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of Hold and a consensus price target of $2.67.

Infinity Pharmaceuticals stock traded down $0.08 during trading hours on Thursday, hitting $1.32. 156,303 shares of the company traded hands, compared to its average volume of 49,050. The company has a current ratio of 7.93, a quick ratio of 9.94 and a debt-to-equity ratio of 0.06. The firm’s 50-day moving average price is $1.63. Infinity Pharmaceuticals has a 1-year low of $1.00 and a 1-year high of $2.92.

Infinity Pharmaceuticals (NASDAQ:INFI) last released its earnings results on Tuesday, July 30th. The biotechnology company reported ($0.18) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.03). The company had revenue of $0.26 million for the quarter, compared to analyst estimates of $2.60 million. Infinity Pharmaceuticals had a negative net margin of 77.80% and a negative return on equity of 42.16%. Research analysts expect that Infinity Pharmaceuticals will post -0.77 earnings per share for the current fiscal year.

Large investors have recently bought and sold shares of the company. Community Bank N.A. boosted its position in shares of Infinity Pharmaceuticals by 71.4% during the 1st quarter. Community Bank N.A. now owns 24,000 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 10,000 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Infinity Pharmaceuticals by 54.2% during the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 45,232 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 15,908 shares in the last quarter. NewSquare Capital LLC boosted its position in shares of Infinity Pharmaceuticals by 98.7% during the 1st quarter. NewSquare Capital LLC now owns 69,548 shares of the biotechnology company’s stock valued at $131,000 after purchasing an additional 34,548 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Infinity Pharmaceuticals by 73.6% during the 4th quarter. Bank of New York Mellon Corp now owns 72,256 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 30,622 shares in the last quarter. Finally, Two Sigma Investments LP boosted its position in shares of Infinity Pharmaceuticals by 29.4% during the 4th quarter. Two Sigma Investments LP now owns 91,296 shares of the biotechnology company’s stock valued at $108,000 after purchasing an additional 20,721 shares in the last quarter. Institutional investors own 54.32% of the company’s stock.

About Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.

Featured Story: Balance Sheet

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Infinity Pharmaceuticals (NASDAQ:INFI)

Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.